Author:
Rehman Jamaal A,Han Gang,Carvajal-Hausdorf Daniel E,Wasserman Brad E,Pelekanou Vasiliki,Mani Nikita L,McLaughlin Joseph,Schalper Kurt A,Rimm David L
Publisher
Springer Science and Business Media LLC
Subject
Pathology and Forensic Medicine
Reference15 articles.
1. Teixido C, Karachaliou N, Gonzalez-Cao M et al, Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015; 12: 87–95.
2. Garon EB, Rizvi NA, Hui R et al, Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 2015; 372: 2018–2028.
3. Borghaei H, Paz-Ares L, Horn L et al, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.
4. Rizvi NA, Mazieres J, Planchard D et al, Activity and safety of nivolumab, an anti-programmed death-protein 1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257–265.
5. Kerr KM, Tsao MS, Nicholson AG et al, Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015; 10: 985–989.
Cited by
133 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献